Finch Therapeutics - About the company
Finch Therapeutics is a public company based in Somerville (United States), founded in 2004 by Jared James Burgess, Tom Borody and Zain Kassam. It operates as a Developer of microbiome-based therapies by using human-first discovery platform. Finch Therapeutics has raised $184M in funding from investors like Shumway Capital, Morgan Noble and Avenir Growth Capital. The company has 3026 active competitors, including 1048 funded and 752 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.
Company Details
Finch Therapeutics is a developer of microbiome-based therapies using a human-first discovery platform. It is using proprietary machine learning techniques to build a clinically annotated library of strains that drive clinical phenotypes of interest. It has also developed an AquaShell for targeted delivery of microbial therapeutics. Its products mainly focussed on Inflammatory Bowel Disease (preclinical), and others.
- Website
- www.finchtherapeutics.com/
- Social
- Email ID
- *****@finchtherapeutics.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2004
Location
Somerville, United States
Stage
Public
Total Funding
$184M in 5 rounds
Latest Funding Round
Investors
Ranked
369th among 3026 active competitors
Annual Revenue
$0 - $1M as on Dec 31, 2023
Employee Count
50 - 199 as on Mar 01, 2026
Exit Details
Public
Legal entities associated with Finch Therapeutics
Finch Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
FINCH THERAPEUTICS GROUP, INC. CIN: 1733257 , United States, Active | Sep 20, 2017 | $0 - $1M (As on Dec 31, 2023) | - | - |
Finch Therapeutics Group, Inc CIN: 6547340 , United States, Active | Sep 20, 2017 | - | 189 (As on Dec 31, 2021) | - |
Finch Therapeutics's IPO details
Finch Therapeutics got listed on Mar 19, 2021.
Click here to take a look at Finch Therapeutics's IPO in detail
Sign up to download Finch Therapeutics' company profile
Finch Therapeutics's funding and investors
Finch Therapeutics has raised a total funding of $184M over 5 rounds. Its first funding round was on Dec 29, 2015. Its latest funding round was a Series D round on Sep 17, 2020 for $*****. 13 investors participated in its latest round. Finch Therapeutics has 21 institutional investors.
Here is the list of recent funding rounds of Finch Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 17, 2020 | 8880430 | Series D | 1839101 | 1978920 | 4220131 | 8945388 |
Jul 19, 2019 | 3959512 | Series C | 6495957 | 7576418 | 3923730 | |
Mar 01, 2018 | 2963253 | Series B | 9144240 | 3823270 | 3567238 |
Access funding benchmarks and valuations. Sign up today!View details of Finch Therapeutics's funding rounds and investors
Finch Therapeutics' founders and board of directors
Founder? Claim ProfileHere are the details of Finch Therapeutics' key team members:
- Jared James Burgess: Co-Founder of Finch Therapeutics and founder of 1 other company. They serve on the board of 1 company.
- Tom Borody: Co-Founder of Finch Therapeutics.
- Zain Kassam: Co-Founder of Finch Therapeutics.
View details of Finch Therapeutics's Founder profiles and Board Members
Finch Therapeutics' employee count trend
Finch Therapeutics has 50 - 199 employees as of Mar 26. Here is Finch Therapeutics's employee count trend over the years:
Uncover Finch Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Finch Therapeutics's Competitors and alternates
Top competitors of Finch Therapeutics include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Finch Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
4th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
369th | Finch Therapeutics 2004, Somerville (United States), Public | Developer of microbiome-based therapies by using human-first discovery platform | $184M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Finch Therapeutics's competitors? Click here to see the top ones
Finch Therapeutics's Investments and acquisitions
Finch Therapeutics has made no investments or acquisitions yet.
Reports related to Finch Therapeutics
Here is the latest report on Finch Therapeutics's geography:
News related to Finch Therapeutics
Filter this listMedia has covered Finch Therapeutics for 1 event in last 1 year, It was about company updates.
•
Boston Biotech Company Finch Therapeutics Files for Chapter 11What Now•Mar 23, 2026•Finch Therapeutics
•
Finch Announces Delisting from Nasdaq and SEC DeregistrationGlobeNewswire•Oct 21, 2024•Finch Therapeutics
•
•
Finch Therapeutics brings on Roivant Sciences' Matthew Blischak as CEOSeeking Alpha•Apr 26, 2023•Finch Therapeutics
•
•
Assertio Appoints Dr. Howard Franklin as Senior Vice President, MedicalGlobeNewswire•Mar 06, 2023•Assertio, Finch Therapeutics
•
Finch halts biotherapeutic trial and axes 95 per cent of its staffBioPharma-Reporter•Jan 26, 2023•Finch Therapeutics
•
Finch stock rises despite abandoning phase 3 trial, cutting ~95% workforceSeeking Alpha•Jan 24, 2023•Finch Therapeutics
•
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal OfficerBusiness Wire•Jan 03, 2023•Finch Therapeutics, Bluebird Bio
•
Finch to lay off 37% of staff after Takeda ends microbiome drug dealBioPharmaDive•Sep 02, 2022•Finch Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Finch Therapeutics
Explore our recently published companies
- Injury Case Funding - United States based, Unfunded company
- Saile Medical - New York City based, 2025 founded, Seed company
- Elm Biosciences - New York City based, 2024 founded, Seed company
- Whoranks - Wien based, 2024 founded, Funding Raised company
- Hedlum - New York City based, 2023 founded, Funding Raised company
- Granted Health - New York City based, 2023 founded, Funding Raised company
